Opportunity Information: Apply for RFA EB 25 002
The Building Biomedical Engineering Education, Research, and Innovation at Historically Black Colleges and Universities (HBCU eBETA) funding opportunity (RFA-EB-25-002) is a National Institutes of Health (NIH) initiative designed to grow and strengthen biomedical engineering, biomedical imaging, and related technology development ecosystems at Historically Black Colleges and Universities (HBCUs). At its core, the program sits within the broader HBCU Biomedical Engineering, Imaging, and Technology Acceleration (BEITA) effort, which aims to expand research capacity, spur technology innovation, and widen education and training opportunities so more of the nation s talent can contribute to high-impact biomedical innovation. The emphasis is not simply on supporting individual projects, but on building durable institutional capability to develop, test, refine, and move promising biomedical technologies toward real-world use.
This opportunity uses the NIH cooperative agreement mechanism and is offered under a UG3/UH3 structure, with clinical trials explicitly not allowed. In practical terms, that generally means awardees should expect an active NIH programmatic role and ongoing collaboration rather than a hands-off grant model, and they should propose work that stays on the preclinical, non-clinical-trial side of the translational pipeline. The intent is to help HBCUs accelerate biomedical engineering and imaging research programs, improve infrastructure and innovation pathways, and increase readiness for technology development and implementation. It also places strong value on education and research training, with a clear goal of preparing HBCU students for careers in biomedical engineering, imaging, and technology (BEIT), including exposure to hands-on research, innovation practices, and pathways that support scientific and professional growth.
Eligibility is centered on HBCUs and U.S.-based higher education institutions, including public and state-controlled institutions of higher education, private institutions of higher education, and other qualifying entities as defined in the announcement. The opportunity is strictly domestic in scope: foreign (non-U.S.) organizations are not eligible to apply, non-domestic components of U.S. organizations are not eligible, and foreign components as defined by the NIH Grants Policy Statement are not allowed. That restriction signals NIH s intent to concentrate capacity-building investments directly within U.S. HBCU environments and their domestic partner networks.
Administratively, this is a discretionary funding opportunity in the health activity category, listed under CFDA 93.286, and it is managed by NIH. The opportunity was created on 2024-10-15, and the listed original closing date is 2025-09-30. While the provided source information does not specify the award ceiling or the expected number of awards, the overall framing makes clear that NIH is seeking proposals that can measurably strengthen biomedical engineering and imaging research capacity at HBCUs, accelerate technology innovation and development, and create structured training and educational experiences that position students and trainees for sustained careers in BEIT fields.Apply for RFA EB 25 002
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Building Biomedical Engineering Education, Research, and Innovation at Historically Black Colleges and Universities (HBCU eBETA) (UG3/UH3 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.286.
- This funding opportunity was created on 2024-10-15.
- Applicants must submit their applications by 2025-09-30. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Public and State controlled institutions of higher education, Private institutions of higher education, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
1. What is the HBCU eBETA funding opportunity?
The Building Biomedical Engineering Education, Research, and Innovation at Historically Black Colleges and Universities (HBCU eBETA) funding opportunity (RFA-EB-25-002) is a National Institutes of Health (NIH) initiative to grow and strengthen biomedical engineering, biomedical imaging, and related technology development ecosystems at Historically Black Colleges and Universities (HBCUs).
2. What larger NIH effort is HBCU eBETA part of?
HBCU eBETA sits within the broader HBCU Biomedical Engineering, Imaging, and Technology Acceleration (BEITA) effort, which aims to expand research capacity, spur technology innovation, and widen education and training opportunities in biomedical engineering, imaging, and technology (BEIT) fields.
3. What is the main purpose of this program?
The program is designed to help HBCUs accelerate biomedical engineering and imaging research programs, improve infrastructure and innovation pathways, and increase readiness for technology development and implementation. A central theme is building durable, institutional capability, not just funding isolated projects.
4. Is the focus on individual research projects or institutional capacity?
The emphasis is not simply on supporting individual projects. The intent is to build lasting institutional capability to develop, test, refine, and move promising biomedical technologies toward real-world use (while staying on the non-clinical-trial side of translation).
5. What scientific and technical areas does this opportunity support?
It supports biomedical engineering, biomedical imaging, and related technology development. The program framing also highlights technology innovation, development, and implementation readiness within BEIT-relevant areas.
6. What funding mechanism does NIH use for this opportunity?
This opportunity uses an NIH cooperative agreement mechanism under a UG3/UH3 structure.
7. What does the cooperative agreement approach imply for applicants?
A cooperative agreement generally means NIH expects an active programmatic role and ongoing collaboration, rather than a hands-off grant relationship. Applicants should anticipate a more interactive partnership with NIH during the project.
8. What is the UG3/UH3 structure?
The announcement indicates a UG3/UH3 structure, which is a phased cooperative agreement format. The provided information does not specify the exact phase transition requirements, but it does indicate NIH expects structured, collaborative work under this mechanism.
9. Are clinical trials allowed under this opportunity?
No. Clinical trials are explicitly not allowed.
10. What kind of work should applicants propose if clinical trials are not allowed?
Applicants should propose work that remains preclinical and does not constitute a clinical trial. The stated intent is to support technology development activities that help move biomedical technologies forward toward real-world use without conducting clinical trials.
11. How does the program address technology translation?
The program aims to strengthen the ability of HBCUs to develop, test, refine, and move promising biomedical technologies toward real-world use. It also emphasizes improving innovation pathways and readiness for technology development and implementation.
12. How important are education and training components in this opportunity?
Education and research training are strongly valued. The opportunity highlights a clear goal of preparing HBCU students for careers in biomedical engineering, imaging, and technology, including exposure to hands-on research, innovation practices, and pathways that support scientific and professional growth.
13. Who is the target trainee and student audience?
The opportunity emphasizes preparing HBCU students and trainees for sustained careers in BEIT fields through structured educational and research training experiences.
14. Who is eligible to apply?
Eligibility is centered on HBCUs and U.S.-based higher education institutions, including public and state-controlled institutions of higher education, private institutions of higher education, and other qualifying entities as defined in the announcement.
15. Is this funding opportunity limited to U.S. organizations?
Yes. The opportunity is strictly domestic in scope.
16. Are foreign (non-U.S.) organizations eligible to apply?
No. Foreign (non-U.S.) organizations are not eligible to apply.
17. Can a U.S. organization include a non-domestic component?
No. Non-domestic components of U.S. organizations are not eligible.
18. Are foreign components allowed under NIH policy definitions?
No. Foreign components, as defined by the NIH Grants Policy Statement, are not allowed.
19. Why does the opportunity restrict foreign organizations and foreign components?
Based on the provided description, the restriction signals NIH intent to concentrate capacity-building investments directly within U.S. HBCU environments and their domestic partner networks.
20. What agency manages this opportunity?
The opportunity is managed by the National Institutes of Health (NIH).
21. What is the activity category for this funding opportunity?
It is listed as a discretionary funding opportunity in the health activity category.
22. What is the CFDA number associated with this opportunity?
The opportunity is listed under CFDA 93.286.
23. What is the opportunity identifier?
The opportunity is identified as RFA-EB-25-002.
24. When was this funding opportunity created?
The opportunity was created on 2024-10-15.
25. What is the original closing date for applications?
The listed original closing date is 2025-09-30.
26. Does the provided information state an award ceiling?
No. The provided information does not specify an award ceiling.
27. Does the provided information state the expected number of awards?
No. The provided information does not specify the expected number of awards.
28. What types of outcomes is NIH looking for from funded projects?
The overall framing indicates NIH is seeking proposals that can measurably strengthen biomedical engineering and imaging research capacity at HBCUs, accelerate technology innovation and development, improve infrastructure and innovation pathways, and create structured training and educational experiences that position students and trainees for sustained careers in BEIT fields.
29. What should applicants keep in mind about the program emphasis?
Applicants should align with the program emphasis on durable institutional capability, collaborative engagement with NIH under a cooperative agreement, non-clinical-trial work, and meaningful education and training experiences tied to biomedical engineering, imaging, and related technology innovation.
Browse more opportunities from the same category: Health
Next opportunity: CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/Developmental Research Projects (R21 Clinical Trial Not Allowed)
Previous opportunity: SCORE-2025-01
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA EB 25 002
Applicants also applied for:
Applicants who have applied for this opportunity (RFA EB 25 002) also looked into and applied for these:
| Funding Opportunity |
|---|
| Mental Health and Psychosocial Support (MHPSS) Program in Ethiopia Apply for 72066325RFI00001 Funding Number: 72066325RFI00001 Agency: Ethiopia USAID-Addis Ababa Category: Health Funding Amount: Case Dependent |
| Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R21 - Clinical Trial Optional) Apply for PAR 25 115 Funding Number: PAR 25 115 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R01 - Clinical Trial Optional) Apply for PAR 25 116 Funding Number: PAR 25 116 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| BURMA: Resilient Tuberculosis Response in Myanmar (RTBR) Activity Apply for 72048225RFA00001 Funding Number: 72048225RFA00001 Agency: Burma USAID - Rangoon Category: Health Funding Amount: $13,500,000 |
| USAID Maisha Bora Activity Apply for 72066024RFA00007 Funding Number: 72066024RFA00007 Agency: Democratic Republic of the Congo USAID-Kinshasa Category: Health Funding Amount: $15,000,000 |
| Strengthening Systems for Health Security Activity (SSHS) Apply for 72052725RFA00001 Funding Number: 72052725RFA00001 Agency: Peru USAID-Lima Category: Health Funding Amount: $19,000,000 |
| TMD Collaborative for IMproving PAtient-Centered Translational Research (TMD IMPACT) (U54 Clinical Trial Optional) Apply for RFA DE 25 003 Funding Number: RFA DE 25 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCD Early Career Research(ECR) Award (R21 Clinical Trial Optional) Apply for PAR 25 120 Funding Number: PAR 25 120 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Comprehensive Analysis, Surveillance, and Statistics Initiative for Diabetes in the Young (CASSIDY) Apply for RFA DP 25 043 Funding Number: RFA DP 25 043 Agency: Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $700,000 |
| Connecting Organizations and People to Empower Diabetes Prevention and Treatment (Connections) Apply for RFA DP 25 041 Funding Number: RFA DP 25 041 Agency: Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $350,000 |
| Epilepsy Incidence Among Children in the United States Apply for RFA DP 25 038 Funding Number: RFA DP 25 038 Agency: Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $500,000 |
| Advancing Public Health Actions to Prevent and Control Chronic Disease in the U.S. Territories and Freely Associated States Apply for CDC RFA DP 25 0024 Funding Number: CDC RFA DP 25 0024 Agency: Centers for Disease Control - NCCDPHP Category: Health Funding Amount: $1,400,000 |
| Centers of Excellence in Maternal and Child Health Education, Science, and Practice Apply for HRSA 25 027 Funding Number: HRSA 25 027 Agency: Health Resources and Services Administration Category: Health Funding Amount: $366,769 |
| Maternal and Child Health Public Health Catalyst Program Apply for HRSA 25 025 Funding Number: HRSA 25 025 Agency: Health Resources and Services Administration Category: Health Funding Amount: $135,000 |
| Behavioral Health Workforce Education and Training Program for Professionals Apply for HRSA 25 068 Funding Number: HRSA 25 068 Agency: Health Resources and Services Administration Category: Health Funding Amount: $600,000 |
| Graduate Psychology Education Program (GPE) Apply for HRSA 25 067 Funding Number: HRSA 25 067 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed) Apply for PAR 25 058 Funding Number: PAR 25 058 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed) Apply for PAR 25 059 Funding Number: PAR 25 059 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed) Apply for PAR 25 060 Funding Number: PAR 25 060 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Centers for Accelerating Phage (Bacteriophage) Therapy to Combat ESKAPE Pathogens (CAPT-CEP) (P01 Clinical Trial Not Allowed) Apply for RFA AI 24 069 Funding Number: RFA AI 24 069 Agency: National Institutes of Health Category: Health Funding Amount: $1,200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA EB 25 002", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.